Topic
Coramsine
About: Coramsine is a research topic. Over the lifetime, 3 publications have been published within this topic receiving 47 citations. The topic is also known as: SBP002.
Papers
TL;DR: The fact that the efficacy of coramsine is potentiated by CpG ODNs suggests thatCoramsine-induced cell death is an immunologic null event.
Abstract: Coramsine is a novel chemotherapeutic agent isolated from Solanum linnaeanum (devil's apple) Topical treatment provides clinical benefit for skin tumors To evaluate the potential broader applicability of the drug, its in vivo anticancer efficacy in a murine model of malignant mesothelioma and its mode of action were investigated Systemic administration of coramsine slowed tumor growth and prolonged survival time Importantly, the antitumor efficacy of coramsine was enhanced when treatment was combined with stimulation of innate immunity using unmethylated CpG-containing oligodeoxynucleotides (ODNs) Combination treatment further slowed tumor growth and provided a survival benefit Coramsine seems to kill tumor cells by direct cell lysis Using 2 different assays to detect apoptosis (caspase activation and DNA fragmentation), we found no evidence that coramsine induces any form of programmed cell death The fact that the efficacy of coramsine is potentiated by CpG ODNs suggests that coramsine-induced cell death is an immunologic null event
35 citations
TL;DR: Coramsine as a 2 hour IV infusion daily x 5 every 2 weeks to define the MTD, recommended Phase II dose, toxicity and pharmacokinetics, and based on preclinical toxicology the infusion was increased to 4 hours at theMTD.
Abstract: 3105 Background: Coramsine (SBP002) is a 1:1 mixture of solasonine and solamargine, plant glycoalkaloids found in the species Solanum linneanum, which have single agent and synergistic combination in vitro and in vivo preclinical efficacy in various tumor models through interaction with rhamnose-containing cell membrane glycoproteins and subsequent internalization. Methods: Coramsine as a 2 hour IV infusion daily x 5 every 2 weeks to define the MTD, recommended Phase II dose, toxicity and pharmacokinetics. Based on preclinical toxicology the infusion was increased to 4 hours at the MTD. Results: 19 previously treated advanced solid tumor pts with PS 0–2 were entered (melanoma 4, renal 4, sarcoma 2, mesothelioma 2, NSCLC 2, other 5). DLT occurred in 2/2 pts at 1.5mg/kg/day (2hr) and 2/2 pts at 3.0mg/kg/day (4hr). Limiting toxicity was grade III/IV transaminitis with grade I-II increases of bilirubin and creatinine. Hepatotoxicity was maximal at days 3–5, resolved over 10–21 days, was clinically asymptomati...
22 citations
TL;DR: Coramsine produces dose-limiting hepatotoxicity at doses above 1.25 mg/kg/day over 24 hours, which exceeds the MTD and activity has been seen against resistant solid tumors.
Abstract: 2070 Background: Coramsine (C) is a 1:1 mixture of solasonine and solamargine, plant glycoalkaloids found in the species Solanum Linneanum, with single agent and synergistic combination in vitro an...
13 citations
Related Topics (5)
Performance Metrics
| Year | Papers |
|---|---|
| 2006 | 2 |
| 2005 | 1 |